AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02199457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Blood pressure will be measured with standard mercury manometer
Study NCT02199457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Body temperature taken with infrared thermometer
Study NCT02199457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
Study NCT02199457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SVSS and reference devices
Description: Measurement of respiration rate
Study NCT02691455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt Glaucoma Implant 350-mm2 / BG101-350
Study NCT02691455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transscleral Diode Laser Cyclophotocoagulation
Description: Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
Study NCT02691455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed Model FP7 Flexible Plate
Study NCT02691455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt Glaucoma Implant 250-mm2 / BG103-250
Study NCT04361357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein
Description: whey protein powder was added on the basis of standardized enteral nutrition preparation.
Study NCT02783404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
Study NCT02783404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Description: Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate
Study NCT02736162 — intervention group
Intervention type: OTHER
Intervention: No treatment (intervention) was administered
Study NCT01170780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: single use of dexamethasone IV 8 mg/2 ml
Study NCT01170780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml IV
Study NCT02270580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PN+
Description: we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors
Study NCT02270580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PN usual
Description: participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
Study NCT02019719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
Study NCT02019719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablets of GSK1278863 matching placebo for oral administration.
Study NCT00094380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTLA4-IgG4m (RG2077)
Study NCT00094380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00865527 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal occult blood test
Description: FOBT
Study NCT00865527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual colonoscopy
Description: computed tomographic colonography
Study NCT00865527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optical colonoscopy
Description: optical (conventional / endoscopic) colonoscopy
Study NCT02972580 — intervention group
Intervention type: GENETIC
Intervention: Genetic characterization
Description: Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
Study NCT01874717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conscious sedation for dental care
Study NCT01874717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conscious sedation for dental care
Study NCT00288119 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
Study NCT01376752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximal cytoreductive surgery
Description: Maximal cytoreductive surgery
Study NCT01376752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal cytoreductive surgery
Description: Maximal cytoreductive surgery
Study NCT01376752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
Study NCT03561779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD302 2ml
Description: YYD302 2ml
Study NCT03561779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Synovian Inj.
Description: Active comparator: Synovian Inj.
Study NCT02172209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Study NCT02172209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bonding
Description: Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bonding
Description: Bonding of upper and lower arches including 2nd maxillary molars with bracket prescription Roth 0.018 inch
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leveling and alignment
Description: Leveling and alignment till 0.016 x0.022 Ni Ti
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leveling and alignment
Description: Leveling and alignment till 0.016 x0.022 Ni Ti
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: Extraction of maxillary 1st premolars
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction
Description: Extraction of maxillary 1st premolars
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retraction
Description: En-masse retraction using 0.017x0.025 TMA T loop
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retraction
Description: En-masse retraction using 0.017x0.025 TMA T loop
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital models
Description: impression taking and digital scanning
Study NCT05875116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The activities will be carried out with the Virtual Reality team, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, on similar equipment and with the same or similar software, at least 1 hour a day, at least 3 days a week.
Study NCT05875116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Description: Physical and occupational therapy activities will be carried out with the paretic upper limb, while the patient has the healthy upper limb attached to the chest, for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, 1 hour a day, at least 3 days a week. In addition, the participant will perform activities of daily living with the free paretic arm and the fixed healthy arm, for 5 hours a day.
Study NCT05875116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physical and Occupational Therapy
Description: The physical and occupational therapy activities that are usually practiced in the Medical Unit will be carried out for 1 hour, twice a week, for 12 sessions (6 weeks). It will be indicated to repeat the activities at home, for 1 hour a day, at least 3 days a week.
Study NCT03593356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly cash gift payments of $333
Description: These subjects receive $333 each month for 76 months via debit card.
Study NCT03593356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly cash gift payments of $20
Description: These subjects receive $20 each month for 76 months via debit card.
Study NCT01216319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nipple reconstruction
Description: Biodesign® Nipple Reconstruction Cylinder
Study NCT00852072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-operator cholangioscopy-guided laser lithotripsy
Description: Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
Study NCT00852072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sphincteroplasty
Description: Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
Study NCT00116207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORAL ANTIOXIDANT
Description: Comparison of triple antioxidant combination therapy vs placebo.
Study NCT00116207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORAL ANTIOXIDANT
Description: Comparison of triple antioxidant combination therapy vs placebo.
Study NCT01466959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrate dialysate (CD)
Description: Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
Study NCT01466959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acetic-acid based dialysate (AD)
Description: Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
Study NCT02102022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 plus modified FOLFOX6
Study NCT01772394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
Study NCT01772394 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
Study NCT01749618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Feedback
Description: Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
Study NCT04537130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IN01 vaccine
Description: INO1 vaccine is a biological compound comprising generated and purified from recombinant bacteria culture that contains a protein consisting of EGF-4-EGF portion and the Cholera Toxin B-Subunit Domain G33D sequence (CTB-G33D) separated by 4 amino acids and 14 amino acids respectively glycine/serine-rich linkers.~IN01 is a recombinant growth factor fusion molecule which, once injected into the patient, stimulates the immune system to produce polyclonal anti-Epidermal Growth Factor (anti-EGF) neutralizing antibodies. This vaccine-led active immunisation is a new approach to target the growth factor pathways allowing for combinations with other small molecule inhibitors in order to obtain a sustained efficacy with an acceptable toxicity.~The vaccine inhibits binding of circulating Epidermal Growth Factor (EGF) to its receptor, EGF-R to block downstream activation of cell signaling pathways contributing to tumor growth or other pathophysiologies such as fibrosis.
Study NCT01063439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Etoposide, Cytarabine, Melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
Study NCT06250621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing.
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital models
Description: impression taking and digital scanning
Study NCT02764671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/0.5ml recombinant hepatitis B vaccine
Description: 5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
Study NCT02568189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
Study NCT02568189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SonoSite Maxx Series Ultrasound System
Description: Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
Study NCT03166709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventing Addiction Related Suicide (PARS)
Description: PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
Study NCT03166709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Outpatient Program standard session
Description: Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
Study NCT03173521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/8.TBG.hARSB
Description: Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Four dose levels are available:~* Starting dose is 6x1011 gc of vector per kg of body weight;~* High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT;~* Very high dose is 6x1012 vector per kg of body weight and will be administered after three subjects at the high dose have experienced no DLT;~* Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg.
Study NCT01104935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab monotherapy
Study NCT01104935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab monotherapy
Study NCT01571323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
Study NCT01571323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
Study NCT01571323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Misoprostol
Description: The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
Study NCT04223336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief physical activity and diet intervention
Description: The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
Study NCT01104935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab and chemotherapy
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measurement
Description: Assessment the rate of retraction for 6 months
Study NCT02742818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Upper body blanket, Bair Hugger
Description: Upper body warming blanket will be used in patients undergoing LEA and EVAR.
Study NCT02742818 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Underbody blanket, Bair Hugger
Description: Underbody warming blanket will be used in patients undergoing LEA and EVAR.
Study NCT03740828 — intervention group
Intervention type: DEVICE
Intervention: KIDScore D3
Description: Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
Study NCT00913861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
Study NCT02446067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.